middle.news
Alterity’s ATH434 Slows Multiple System Atrophy Progression with Strong Phase 2 Data
6:45pm on Sunday 1st of June, 2025 AEST
•
Healthcare
Read Story
Alterity’s ATH434 Slows Multiple System Atrophy Progression with Strong Phase 2 Data
6:45pm on Sunday 1st of June, 2025 AEST
Key Points
ATH434 achieved statistically significant slowing of disease progression on UMSARS I scale
Reduction and stabilization of brain iron concentrations confirmed by MRI biomarkers
Maintained brain volume compared to placebo over 12 months
Favorable safety profile with no drug-related serious adverse events
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Alterity Therapeutics (ASX:ATH)
OPEN ARTICLE